Peter Verhamme
Katholieke Universiteit Leuven
H-index: 74
Europe-Belgium
Top articles of Peter Verhamme
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Mortality and cardiovascular end points in relation to the aortic pulse wave components: An individual-participant meta-analysis | Hypertension | Gavin R Norton De-Wei An Lucas S Aparicio Yu-Ling Yu Fang-Fei Wei | 2024/5 |
Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry | Journal of the American Geriatrics Society | Ludovic Lafaie Géraldine Poenou Olivier Hanon Luciano López‐Jiménez José Antonio Nieto | 2024/1 |
Factor XI Inhibitors: Potential Role in End-Stage Kidney Disease | Matthew Ades Camille Simard Thomas Vanassche Peter Verhamme John Eikelboom | 2024/1/24 | |
Clinical presentation and outcomes of patients with cancer-associated isolated distal deep vein thrombosis | Journal of Clinical Oncology | Jean-Philippe Galanaud Javier Trujillo-Santos Behnood Bikdeli Laurent Bertoletti Pierpaolo Di Micco | 2024/2/10 |
The current landscape of Factor XI inhibitors | Matthias M Engelen Charlotte Van Edom Andreas Verstraete Peter Verhamme Thomas Vanassche | 2024/4/16 | |
Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions | Clinical Pharmacokinetics | Lorenz Van der Linden Thomas Vanassche Lucas Van Aelst Peter Verhamme | 2024/1/18 |
Etranacogene Dezaparvovec Shows Sustained Efficacy and Safety in Adult Patients With Severe or Moderately Severe Haemophilia B 3 Years After Administration in the HOPE-B Trial | Hämostaseologie | S Pipe P van der Valk P Verhamme P Kampmann F Leebeek | 2024/2 |
Thrombophilia Testing: from Genetic Predisposition to Discrimination | TH Open | Andreas Verstraete Kathleen Freson Peter Verhamme Thomas Vanassche | 2024/4 |
Clotting of the Extracorporeal Circuit in Hemodialysis: Beyond Contact-Activated Coagulation | Matthias M Engelen Peter Verhamme Thomas Vanassche | 2024/1/16 | |
Adults With Haemophilia B and History of Chronic HCV/HBV Infection Receiving Etranacogene Dezaparvovec Gene Therapy in the HOPE-B Clinical Trial Demonstrate Long-Term Bleeding … | Hämostaseologie | A von Drygalski N O’Connell P Verhamme K Meijer P van der Valk | 2024/2 |
Enoxaparin for Long-Term Therapy of Venous Thromboembolism in Patients with Cancer and Renal Insufficiency | Thrombosis and Haemostasis | Patricia Sigüenza Juan J López-Núñez Conxita Falgá Covadonga Gómez-Cuervo Antoni Riera-Mestre | 2024/4 |
Age-related differences in the presentation, management, and clinical outcomes of 100,000 patients with venous thromboembolism in the RIETE registry | Archivos de Bronconeumología | Alberto García Ortega David Jiménez Ana Pedro-Tudela Cristina Pérez-Ductor Carmen Fernández-Capitán | 2024/1/3 |
Incidence and predictors of post-thrombotic syndrome in patients with proximal DVT in a real-world setting: findings from the GARFIELD-VTE registry | Journal of thrombosis and thrombolysis | Paolo Prandoni Sylvia Haas Meg E Fluharty Sebastian Schellong Harry Gibbs | 2024/2 |
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial | The Lancet Haematology | Michiel Coppens Steven W Pipe Wolfgang Miesbach Jan Astermark Michael Recht | 2024/3/1 |
The science and art of predicting recurrent VTE | Marc Carrier Peter Verhamme | 2024/1/1 | |
OSTEO18, a novel urinary proteomic signature, associated with osteoporosis in heart transplant recipients | Heliyon | Yu-Ling Yu Qi-Fang Huang De-Wei An Julia Raad Dries S Martens | 2024/1/30 |
Therapy and guideline adherence at a multidisciplinary hypertension clinic: A prospective, observational study | Vascular Pharmacology | Julie Hias Lise Defieuw Thomas Vanassche Peter Verhamme Lorenz Van der Linden | 2024/3/1 |
Final study report of andexanet alfa for major bleeding with factor Xa inhibitors | Circulation | Truman J Milling Jr Saskia Middeldorp Lizhen Xu Bruce Koch Andrew Demchuk | 2023/3/28 |
From bad to worse: the shortage of fibrinolytics | Lorenz Roger Van der Linden Jens Neefs Thomas Vanassche Robin Lemmens Peter Verhamme | 2023/5/1 | |
36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE | Thrombosis research | Alexander GG Turpie Alfredo E Farjat Sylvia Haas Walter Ageno Jeffrey I Weitz | 2023/2/1 |
Co-Authors
